Approved the Audited Financial Results for the quarter and year ended March 31, 2025 along with unmodified auditors report issued by statutory auditor.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shentracon Chemicals' board approved audited financial results for Q4 and FY ended March 31, 2025. The company reported zero sales from operations across all periods, with total revenue of just Rs. 17.66 lakhs for FY25 (vs Rs. 0.02 lakhs in FY24), entirely from other income like interest and investment gains. The company posted a loss after tax of Rs. 29.90 lakhs for FY25, worse than the Rs. 10.70 lakh loss in FY24, hit by a Rs. 30.34 lakh extraordinary charge for premium paid on preference share redemption. Auditor Chanani & Associates gave an unmodified opinion. The board decided not to recommend any dividend for FY25, citing growth plans and uncertain environment.
Negative for shareholders - the company has no operational business, negative net worth (around Rs. -9.96 lakhs as disclosed), deeply negative operating cash flow of Rs. -154.65 lakhs, and worsening losses. The stock is not attractive for income investors as no dividend was declared, and the weak financial position raises serious concerns about long-term viability.